Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases : combined results from two multicentre trials
Nom du journal : Eur J Cancer
Année : 2003
Volume : 39
Page de départ : 1228
Page de fin : 1233